论文部分内容阅读
目的对比吉西他滨联合顺铂方案与多西他赛联合奈达铂方案治疗晚期肺鳞癌的治疗效果。方法将晚期肺鳞癌患者60例随机分为2组各30例,GP组采用吉西他滨联合顺铂方案,TN组采用多西他赛联合奈达铂方案化疗,比较2组患者的治疗效果、不良反应及生存率。结果 GP组患者总有效率为40.00%,TN组总有效率为30.00%,2组比较差异无统计学意义(P>0.05)。GP组WBC减少、PLT减少发生率高于TN组,末梢神经毒性、脱发发生率低于TN组,差异均有统计学意义(P<0.05)。GP组6个月、1年、1.5年、2年生存率均高于TN组,差异均有统计学意义(P<0.05)。结论采用吉西他滨联合顺铂方案治疗晚期肺鳞癌患者能延长生存期,且安全性好。
Objective To compare the efficacy of gemcitabine plus cisplatin and docetaxel combined with nedaplatin in the treatment of advanced squamous cell carcinoma of the lung. Methods Sixty patients with advanced squamous cell carcinoma of the lung were randomly divided into two groups of 30 cases. The GP group was treated with gemcitabine and cisplatin. The TN group was treated with docetaxel combined with nedaplatin. The curative effect and adverse effect of the two groups were compared Response and survival rate. Results The total effective rate was 40.00% in GP group and 30.00% in TN group. There was no significant difference between the two groups (P> 0.05). In GP group, WBC decreased, PLT decreased more than TN group, peripheral neurotoxicity and hair loss were lower than TN group (P <0.05). The 6-month, 1-year, 1.5-year and 2-year survival rates in GP group were significantly higher than those in TN group (P <0.05). Conclusion Gemcitabine combined with cisplatin in patients with advanced lung squamous cell carcinoma can prolong survival and safety.